Clinical Report: Emerging Insights on Circulating Tumor DNA in Sarcoma

Background

Sarcomas are rare tumors with significant genomic diversity, complicating diagnosis and treatment. Traditional imaging methods often fail to detect early recurrences, highlighting the need for improved monitoring techniques.

Data Highlights

No numerical data available in the source material.

Key Findings

• Sarcomas encompass over 100 histological and molecular subtypes, complicating clinical management.
• ctDNA levels correlate with tumor dynamics and may assist in monitoring treatment response and recurrence.
• Current literature on ctDNA in sarcoma is limited to small, retrospective studies.
• ctDNA may help stratify patients for intensive monitoring or treatment de-escalation based on post-surgical levels.
• Future research is needed to define the role of ctDNA in sarcoma management.

Clinical Implications

Ongoing research may clarify the utility of ctDNA in guiding clinical decisions.

Conclusion

Further studies are needed to establish the clinical applications and effectiveness of ctDNA in sarcoma management.

Related Resources & Content

1. ASCO Post, 2023 -- Using Circulating Tumor DNA to Predict Early Recurrence of Soft-Tissue Sarcomas
2. ASCO Post, 2025 -- Advancing Clinical Decisions With Circulating Tumor DNA: Insights From Recent Clinical Trials
3. ASCO Post, 2025 -- Circulating Tumor DNA–Guided Risk Stratification in Colorectal Cancer: Evolving Evidence and Future Utility KEY POINTS
4. ASCO Guideline, 2026 -- Circulating Tumor DNA Testing in Solid Tumors and Lymphoma
5. ESMO Recommendations, 2025 -- Clinical Reporting of Genomic Test Results for Solid Cancers
6. The ASCO Post — Liquid Biopsy: Mounting Evidence Shows Clinical Utility in Tumor Monitoring
7. Circulating Tumor DNA Testing in Solid Tumors and Lymphoma: ASCO Guideline | JCO Oncology Practice
8. ESMO Recommendations on clinical reporting of genomic test results for solid cancers
9. Ultra-sensitive whole-genome sequencing–based molecular residual disease detection in resectable sarcoma in MONSTAR-SCREEN-3. | Journal of Clinical Oncology
10. Circulating tumor DNA monitoring for early detection of disease recurrence in bone/soft tissue sarcoma. | Journal of Clinical Oncology
11. Early assessment of response to chemotherapy via ctDNA in soft tissue sarcoma. | Journal of Clinical Oncology
12. SUMMARY OF SAFETY AND EFFECTIVENESS DATA (SSED)
13. Current Evidence for Circulating Tumor DNA in Sarcoma: Challenges and Opportunities for Clinical Application - PubMed
14. Clinical utilisation and survival correlation of blood-based liquid biopsy in sarcoma - A systematic review and meta-analysis - ScienceDirect
15. An international framework for clinical translation of molecular classifiers in osteosarcoma - PubMed